Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT. But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders.

Radiopharmaceutical manufacturer secures $30M to bolster domestic isotope production
Although the company is already bringing in revenue from medical radioisotopes, the new funding will help further these initiatives and drive additional research and development.
Department of Energy, Shine working on $263M deal to establish Mo-99 supply in US
If approved, the funds would go toward the completion of Chrysalis—Shine's first-of-its-kind medical isotope production facility.
Radiopharma firm secures $85M to expand domestic production of radioisotopes
SpectronRx announced the funding on April 2, highlighting the critical need for a reliable domestic supply of radiopharmaceuticals.
Department of energy partners to bolster domestic radioisotope supply
Gadolinium-153, or Gd-153, is routinely used to calibrate nuclear imaging equipment. It has been in short supply since 2023 when global distribution of the radioisotope came to a halt.
Health system touts $7M expansion of molecular imaging department, ER
Leaders at the Utah hospital are hopeful the newly updated PET offerings will help patients seek treatment locally, avoiding long travel times.

NIH provides $10M push for gender equality in biomedical research

The U.S. National Institutes of Health (NIH) has set an initiative in motion that intents to banish a biomedical research bias toward the use of male animal models and cells in preclinical studies.

Mediso reaches another milestone with 150th installation of preclinical integrated multimodality imaging system

Mediso Medical Equipment Developing and Service Ltd. is proud to announce the hundred and fiftieth installation of Mediso manufactured, integrated preclinical imaging systems, at the prestigious Edinburgh University.

Video lecture: Nanoconstructs in theranostics

Watch a presentation on nanoconstructs in cancer theranostics from the Methodist Hospital Research Institute and Tel Aviv University (TAU) posted online from the recent Summer School on Nanomedicine and Innovation.

Mevion Medical Systems introduces Hyperscan for the Mevion S250 platform

Hyperscan is debuting at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), held September 14 – 16 in San Francisco.  Mevion representatives will formally introduce Hyperscan at booth 728 in the exhibit hall.

Agendia test for molecular subtyping of breast cancer is a better guide to pre-surgical treatment

In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast cancer than does conventional IHC-FISH pathology testing.

Eli Lilly funds lawsuit against CMS for limiting amyloid imaging

Makers of F-18 florbetapir (Amyvid) are bankrolling a lawsuit against the Centers for Medicare & Medicaid Services (CMS), which hampered coverage of amyloid imaging earlier this year as a means for ruling out Alzheimer’s disease. The lawsuit was filed in federal court by Lilly and others Sept. 5, according to this Wall Street Journal report.

CMS: Slow growth in U.S. health spending

The Centers for Medicare & Medicaid Services (CMS) has provided projected U.S. healthcare spending for the next several years and it is modest. Due to a timid economy and higher private insurance plan costs that pinch demand for healthcare services, average annual healthcare spending is expected to grow by 5.7 percent this year and just about 6 percent from 2013 to 2023.

Agendia announces study showing molecular subtyping can improve breast cancer treatment

In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use of conventional IHC-FISH pathology tests.

Molecular Imaging

Radiopharmaceutical manufacturer secures $30M to bolster domestic isotope production

Department of Energy, Shine working on $263M deal to establish Mo-99 supply in US

Radiopharma firm secures $85M to expand domestic production of radioisotopes

Department of energy partners to bolster domestic radioisotope supply

Health system touts $7M expansion of molecular imaging department, ER